Article
Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.
European journal of clinical pharmacology - 1 Nov 2018
Mugusi Sabina, Ngaimisi Eliford, Janabi Mohammed, Mugusi Ferdinand, Minzi Omary, Aris Eric, Bakari Muhammad, Bertilsson Leif, Burhenne Juergen, Sandstrom Eric, Aklillu Eleni
Abstract excerpt
PURPOSE: Efavirenz-based combination antiretroviral therapy (cART) is associated with neuropsychiatric adverse events. We investigated the time to onset, duration, clinical implications, impact of pharmacogenetic variations, and anti-tuberculosis co-treatment on efavirenz-associated neuropsychiatric manifestations. METHODS: Prospective cohort study of cART naïve HIV patients with or without tuberculosis (HIV-TB)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
